Now showing 1 - 3 of 3
  • Publication
    "Putting the power back into community": A mixed methods evaluation of a chronic hepatitis B training course for the Aboriginal health workforce of Australia's Northern Territory.
    (2024-01-24)
    ;
    ;
    Vintour-Cesar, Emily
    ;
    ;
    ;
    Garambaka Gurruwiwi, George
    ;
    ;
    Bukulatjpi, Sarah Mariyalawuy
    ;
    ;
    Ross, Cheryl
    ;
    Stuart-Carter, Kelly-Anne
    ;
    Ngurruwuthun, Terese
    ;
    Dhagapan, Amanda
    ;
    ;
    Sullivan, Richard
    ;
    Ward, Linda
    ;
    Schroder, Phoebe
    ;
    ;
    Davis, Joshua S
    ;
    ;
    BACKGROUND: Chronic hepatitis B (CHB) is endemic in the Aboriginal and Torres Strait Islander population of Australia's Northern Territory. Progression to liver disease can be prevented if holistic care is provided. Low health literacy amongst health professionals is a known barrier to caring for people living with CHB. We co-designed and delivered a culturally safe "Managing hepatitis B" training course for the Aboriginal health workforce. Here, we present an evaluation of the course. OBJECTIVES: 1. To improve course participants CHB-related knowledge, attitudes, and clinical practice. 2. To evaluate the "Managing hepatitis B" training course. 3. To enable participants to have the skills and confidence to be part of the care team. METHODS: We used participatory action research and culturally safe principles. We used purpose-built quantitative and qualitative evaluation tools to evaluate our "Managing hepatitis B" training course. We integrated the two forms of data, deductively analysing codes, grouped into categories, and assessed pedagogical outcomes against Kirkpatrick's training evaluation framework. RESULTS: Eight courses were delivered between 2019 and 2023, with 130 participants from 32 communities. Pre- and post-course questionnaires demonstrated statistically significant improvements in all domains, p<0.001 on 93 matched pairs. Thematic network analysis demonstrated high levels of course acceptability and significant knowledge acquisition. Other themes identified include cultural safety, shame, previous misinformation, and misconceptions about transmission. Observations demonstrate improvements in post-course engagement, a deep understanding of CHB as well as increased participation in clinical care teams. CONCLUSIONS: The "Managing hepatitis B" training course led to a sustained improvement in the knowledge and attitudes of the Aboriginal health workforce, resulting in improved care and treatment uptake for people living with CHB. Important non-clinical outcomes included strengthening teaching and leadership skills, and empowerment.
      1353
  • Publication
    Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across Australia.
    (2024-03-31)
    Wang, Dao Sen
    ;
    Phu, Amy
    ;
    McKee, Kristen
    ;
    Strasser, Simone I
    ;
    Sheils, Sinead
    ;
    Weltman, Martin
    ;
    Sellar, Sue
    ;
    Davis, Joshua S
    ;
    Young, Mel
    ;
    Braund, Alicia
    ;
    Farrell, Geoffrey C
    ;
    Blunn, Anne
    ;
    Harding, Damian
    ;
    Ralton, Lucy
    ;
    Muller, Kate
    ;
    Davison, Scott A
    ;
    Shaw, David
    ;
    Wood, Marnie
    ;
    Hajkowicz, Krispin
    ;
    Skolen, Richard
    ;
    ;
    ;
    Doyle, Adam
    ;
    Tuma, Rhoda
    ;
    Hazeldine, Simon
    ;
    Lam, Wendy
    ;
    Edmiston, Natalie
    ;
    Zohrab, Krista
    ;
    Pratt, William
    ;
    Watson, Belinda
    ;
    Zekry, Amany
    ;
    Stephens, Carlie
    ;
    Clark, Paul J
    ;
    Day, Melany
    ;
    Park, Gordon
    ;
    Kim, Hami
    ;
    Wilson, Mark
    ;
    McGarity, Bruce
    ;
    Menzies, Natalie
    ;
    Russell, Darren
    ;
    Lam, Thao
    ;
    Boyd, Peter
    ;
    Kok, Jen
    ;
    George, Jacob
    ;
    Douglas, Mark W
    Hepatitis C virus (HCV) infection can now be cured with well-tolerated direct-acting antiviral (DAA) therapy. However, a potential barrier to HCV elimination is the emergence of resistance-associated substitutions (RASs) that reduce the efficacy of antiviral drugs, but real-world studies assessing the clinical impact of RASs are limited. Here, an analysis of the impact of RASs on retreatment outcomes for different salvage regimens in patients nationally who failed first-line DAA therapy is reported.We collected data from 363 Australian patients who failed first-line DAA therapy, including: age, sex, fibrosis stage, HCV genotype, NS3/NS5A/NS5B RASs, details of failed first-line regimen, subsequent salvage regimens, and treatment outcome.Of 240 patients who were initially retreated as per protocol, 210 (87.5%) achieved sustained virologic response (SVR) and 30 (12.5%) relapsed or did not respond. The SVR rate for salvage regimens that included sofosbuvir/velpatasvir/voxilaprevir was 94.3% (n = 140), sofosbuvir/velpatasvir 75.0% (n = 52), elbasvir/grazoprevir 81.6% (n = 38), and glecaprevir/pibrentasvir 84.6% (n = 13). NS5A RASs were present in 71.0% (n = 210) of patients who achieved SVR and in 66.7% (n = 30) of patients who subsequently relapsed. NS3 RASs were detected in 20 patients (20%) in the SVR group and 1 patient in the relapse group. NS5B RASs were observed in only 3 patients. Cirrhosis was a predictor of relapse after retreatment, as was previous treatment with sofosbuvir/velpatasvir.In our cohort, the SVR rate for sofosbuvir/velpatasvir/voxilaprevir was higher than with other salvage regimens. The presence of NS5A, NS5B, or NS3 RASs did not appear to negatively influence retreatment outcomes.
      20
  • Publication
    Engagement and partnership with consumers and communities in the co-design and conduct of Research: Lessons from the INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis (INFERR) clinical trial.
    (2024-07-15)
    Long, Stephanie
    ;
    Ross, Cheryl
    ;
    Koops, Joan
    ;
    Coulthard, Katherine
    ;
    Nelson, Jane
    ;
    Shapkota, Archana Khadka
    ;
    Hewett, Leiana
    ;
    ;
    Graham, Jessica
    ;
    ;
    ;
    Hoppo, Libby
    ;
    ;
    Pawar, Basant
    ;
    ;
    Gold, Lorna Murakami
    ;
    Rathnayake, Geetha
    ;
    ;
    ;
    ;
    ;
    ;
    ;
    ;
    ;
    ;
    ;
    Lawton, P
    ;
    Barzi, Federica
    ;
    ;
    Mayo, Mark
    ;
    Cass, Alan
    ;
    Engagement and partnership with consumers and communities throughout research processes produces high quality research meeting community needs and promoting translation of research into improved policy and practice. Partnership is critical in research involving Aboriginal and/or Torres Strait Islander people (First Nations Peoples) to ensure cultural safety. We present lessons from the design, implementation and progress of the National Health and Medical Research Council funded INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on hemodialysis (INFERR) clinical trial.The trial was designed to understand the benefits and harms of iron therapy in First Nations Australians on haemodialysis with anaemia and hyperferritinaemia. The lack of evidence for treatment was discussed with patients who were potential participants. A key element ensuring safe conduct of the INFERR trial was the establishment of the Indigenous Reference Groups (IRGs) comprising of dialysis patients based in the Top End of Australia and Central Australia. Two IRGs were needed based on advice from First Nations communities and researchers/academics on the project regarding local cultural differences and approaches to trial conduct. The IRGs underpin culturally safe trial conduct by providing input into study materials and translating study findings into effective messages and policies for First Nations dialysis patients. Throughout the trial conduct, the IRGs' role has developed to provide key mechanisms for advice and guidance regarding research conduct both in this study and more broadly. Support provided to the IRGs by trial First Nations Research Officers and independent First Nations researchers/academics who simplify research concepts is critical. The IRGs have developed feedback documents and processes to participants, stakeholders, and the renal units. They guarantee culturally safe advice for embedding findings from the trial into clinical practice guidelines ensuring evidence-based approaches in managing anaemia in haemodialysis patients with hyperferritinaemia.Active consumer and community partnership is critical in research conduct to ensure research impact. Strong partnership with consumers in the INFERR clinical trial has demonstrated that First Nations Consumers will engage in research they understand, that addresses health priorities for them and where they feel respected, listened to, and empowered to achieve change.In this paper, we present the importance of actively involving consumers in the planning, implementation and conduct of research using the example of a clinical trial among Aboriginal and/or Torres Strait Australians (First Nations Australians) who have kidney disease and are currently receiving haemodialysis. The study assesses how safe and effective it is for people on dialysis to receive iron given through the vein during dialysis when they have anaemia and high levels of a blood test called ferritin, a test used routinely to measure iron levels. Two consumer reference groups of First Nations patients on dialysis, one based in the Top End of Australia and the other based in Central Australia, are supported by First Nations Research Officers and Research Academics to make sure that the research is performed in a way that involves, respects and values First Nations participation, culture, and knowledge. Active consumer and community partnership in this study has supported robust research governance processes which we believe are crucial for knowledge translation to have a positive impact for patients.
      7